Pharmaceutical-Technology.com

Pharmaceutical-technology.com is part of a network of over 30 specialized B2B websites, reaching a vast global audience of active decision-makers, influencers, and thought leaders. Together, these platforms attract 55 million industry professionals each year. Being a part of GlobalData, we have access to an extensive database with over 1 billion data points that cover companies, deals, projects, forecasts, and trends. This wealth of information fuels our top-tier content. Our expertise spans more than 80 global markets and is supported by a dedicated team of over 800 award-winning journalists, researchers, and analysts, providing you with essential insights that can influence business outcomes. Our unique marketing solution combines award-winning targeting technology with our network of websites, offering a comprehensive approach that integrates insight, creativity, and advanced AI technology. This allows our clients to effectively identify, target, and engage with potential customers through access to our 30+ B2B media sites and their extensive sector-specific audiences. With unmatched reach, targeted data, and first-party data capabilities, we create outstanding campaigns for our clients. To learn more about our technology-driven marketing solution, please visit https://www.verdictmediastrategies.com/.

International, Trade/B2B

English

Magazine

Outlet metrics

Domain Authority

Ranking

Global

#231255

United States

#146838

Health/Pharmacy

#295

Traffic sources

Monthly visitors

Articles

Roche plans $700m manufacturing plant in the US - Pharmaceutical Technology

2 days ago | pharmaceutical-technology.com | Jenna Philpott

The new site will support Roche and its unit Genentech's future portfolio of next-generation obesity medicines. Roche’s planned facility in North Carolina will create 400 jobs. Credit: jetcityimage via Getty Images. Roche is deepening its manufacturing footprint in the US with plans to invest more than $700m in a new production facility in Holly Springs, North Carolina, aimed at supporting its pipeline of next-generation obesity drugs.
The advantages of isolator lines for large-scale pharma manufacturing

2 days ago | pharmaceutical-technology.com | Fi Forrest

Isolator lines play a crucial role in the pharmaceutical industry by providing a sterile environment for drug products while protecting operators from exposure to hazardous substances. They also present several significant advantages for large-scale aseptic filling, as Marcel Langner of IDT Biologika explains. IDT Biologika filling line. Credit: IDT Biologika.
Trump to sign order tying US drug prices to global rates

2 days ago | pharmaceutical-technology.com | Jenna Philpott

The executive order aims to cut US prescription drug costs by linking them to the lowest prices paid internationally. Trump has announced that he will sign a global drug price match policy. Credit: Anna Moneymaker via Getty Images. In a renewed push to overhaul pharmaceutical pricing in the US, President Donald Trump announced he will sign an executive order to link US drug prices to those paid in other countries.
Valneva’s chikungunya vaccine use halted in older adults amid safety concerns

3 days ago | pharmaceutical-technology.com | Robert Barrie

Both the FDA and EMA have suspended Ixchiq’s use in older adults after post-marketing serious adverse events that include two deaths. Shares in the French vaccine maker have slid over the past few days following the start of the investigations. Image credit: Shutterstock/ Ink Drop.
Bavarian Nordic shares rise 7% following strong Q1 for vaccine sales

5 days ago | pharmaceutical-technology.com | Robert Barrie

Bavarian Nordic faced a challenging close to 2024, with Q3 revenue falling 26% compared to the same interval in 2023. Bavarian Nordic has recently secured had key vaccine approvals for chikungunya virus and mpox/smallpox. Image credit: Shutterstock / Anne Czichos. Bavarian Nordic is successfully navigating a sentiment-changing vaccine landscape, posting Q1 revenues significantly up from the same period in 2024.
FDA chief Martin Makary sets June deadline for genAI rollout

5 days ago | pharmaceutical-technology.com | Ross Law

The FDA’s agency-wide genAI rollout is being led by Jeremy Walsh, the recently appointed chief AI officer. According to FDA commissioner Dr Makary, the time for talk on genAI is over, with now the right time to implement the technology at the FDA. Image credit: Tada Images / Shutterstock. The US Food and Drug Administration (FDA) has set an “aggressive” timeline to implement generative artificial intelligence (genAI) across the agency by 30 June 2025.
VC firm Vivo Capital outlays $740m for biotech investment

6 days ago | pharmaceutical-technology.com | Robert Barrie

Vivo Capital has previously backed biotechs acquired by big pharma in billion-dollar deals. Vivo Capital has invested in 430 public and private companies since it was founded in 1996. Image credit: Shutterstock/ Pixelbliss. Set against a backdrop of barren biotech investment, Vivo Capital has secured $740m to back preclinical and clinical-stage life science companies.
FDA plans to expand unannounced inspections of foreign drug plants - Pharmaceutical Technology

1 week ago | pharmaceutical-technology.com | Jenna Philpott

This move comes a day after President Trump signed an executive order to streamline approval processes for domestic plants. President Donald Trump signed the executive order on 5 May. Credit: ALEX WROBLEWSKI via Getty Images. The US Food and Drug Administration (FDA) is moving to tighten oversight of foreign manufacturers supplying the US market by subjecting overseas facilities to unannounced inspections, which has long been the standard for domestic producers.
European biotechs must understand US culture while seeking funding

1 week ago | pharmaceutical-technology.com | Abigail Beaney

At a time when investment has been low in biotech, establishing and maintaining good relationships with investors is vital. If European companies are looking to the US for investment, they must understand and accept US culture. Credit: Shutterstock/Melnikov Dmitriy. At a time when the US is becoming more self-focused, European biotechs must understand and appreciate US culture when seeking funding, an expert panel has said.
Novo Nordisk cuts 2025 outlook due to compounding-hit Wegovy demand

1 week ago | pharmaceutical-technology.com | Robert Barrie

Shares in Novo Nordisk were still up after Q1 2025 witnessed a total revenue jump by 18%, compared to Q1 2024. Novo Nordisk is the second largest company in Europe by market cap. Image credit: Shutterstock/ Tada Images. Novo Nordisk has reduced its sales and profits forecasts for 2025 due to lower-than-expected demand in the US for blockbuster weight loss and diabetes drugs, though shares in the company were still up following positive Q1 results.